The study highlights the safety, efficacy, and feasibility of transiently opening the BBB in brain regions affected by Parkinson’s and the future possibility of ultrasound-assisted drug delivery (neurotrophins, antibodies, anti-inflammatories, etc.)to brain regions to slow the progression of Parkinson’s disease [96]. This evidence concerns the gene BDNF and Parkinson disease.